HOME / INVESTORS / BOARD OF DIRECTORS AND CEO

Background and education: Founder and former CEO and Development and Product Manager at Glycorex Transplantation AB. Currently CEO of the subsidiary Glycoprobe. Doctor of Technology in Chemistry and Applied Biochemistry from Lund University. Associate Professor in Biotechnology.


Shareholdings, including related holdings: 3,268,000 A-shares and 3,959,051 B-shares.

Richard Lundin
Member of the board since 2026
Born: 1961

Education: Master of Science and Business Administration, Karlstads University
Background: Business leader with extensive experience in diagnostics and transfusion medicine. Has held senior positions in Svenska Labex AB, including CEO, and broad experience in business development, strategy and international markets. Is a partner and since January 2025 CEO of Lundair Freeze AB, with a focus on the development and commercialization of technology for rapid freezing of blood plasma. Has solid experience in procurement, product launches and working on boards of growth companies.

Shareholding: 0 shares

Fredrik Johansson
Member of the board since 2023
Born: 1988

Education and Background: Medical Doctorate from Lund University, active researcher, and Associate Professor at the Faculty of Medicine. Author of scientific publications and textbooks. Experience in various leadership roles in national and international medical organizations. Engaged in private investments and portfolio management, particularly within the biotech and MedTech sectors for over 10 years.


Shareholding: Private and through companies: 37,500.

Roland Frösing
Member of the board since 2024
Born: 1960

Education and Background: Doctor of Medicine from the University of Gothenburg. 15 years of experience at Sahlgrenska University Hospital in various fields including surgery. Over 20 years of experience in pharmaceutical and medical technology companies: Pfizer, Fujisawa Scandinavia, Astellas Pharma, Mölnlycke, MediWound, Abigo Medical. Board assignments in, among others, S2Medical and RLS Global. Currently, Chief Medical Officer at Rewell Medical and Medical Adviser to Wellspect and Essity.

Shareholding: 0 shares

Carl-Magnus Schultz